STOCK TITAN

ProMIS Neurosciences, Inc. - $PMN STOCK NEWS

Welcome to our dedicated page for ProMIS Neurosciences news (Ticker: $PMN), a resource for investors and traders seeking the latest updates and insights on ProMIS Neurosciences stock.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect ProMIS Neurosciences's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of ProMIS Neurosciences's position in the market.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.3%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.54%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.16%
Tags
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.46%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.11%
Tags
none
-
Rhea-AI Summary
ProMIS Neurosciences announces data supporting potential targets for ALS and FTLD-TDP, as well as updated preclinical data for Alzheimer's candidate PMN310.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.38%
Tags
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.55%
Tags
none
-
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6%
Tags
conferences clinical trial
ProMIS Neurosciences, Inc.

Nasdaq:PMN

PMN Rankings

PMN Stock Data

30.15M
10.81M
24.35%
17.71%
0.13%
Research and Development in Biotechnology
Professional, Scientific, and Technical Services
Link
United States of America
TORONTO

About PMN

promis™ neurosciences, inc. (tse: pmn, https://ca.finance.yahoo.com/q/bc?s=pmn.to), is a development stage biotech company that discovers and develops precision therapeutics and companion diagnostics for early detection and effective treatment of neurodegenerative diseases, in particular alzheimer’s disease (ad) and amyotrophic lateral sclerosis (als). the company’s scientific foundation centers on the growing knowledge base relating to diseases characterized by the presence of abnormal, misfolded proteins. several neurodegenerative diseases exhibit protein misfolding, such as ad, als, and parkinson’s disease (pd). recent published evidence indicates that for a given misfolded protein there exist multiple prion-like strains, each strain representing a specific target against which specific therapeutics can be developed. the company is focused on the discovery and development of precision therapeutics and companion diagnostics to combat the several strains of beta-amyloid (aβ) and tau i